BHC
HealthcareBausch Health Companies Inc.
$4.93-0.12 (-2.28%)
Prev Close
$5.05
Open
$5.10
High
$5.10
Low
$4.93
Volume
1.67M
Market Cap
$1.97B
P/E
11.75
Div Yield
—
Over the past 12 months, insider activity at Bausch Health Companies Inc. (BHC) has been dominated by buying, with 4 insider purchases totaling $369.63M and 3 insider sales totaling $742.9K. The most recent insider transaction was by Carson Seana (EVP, General Counsel), who sold $475.1K worth of shares on Sep 5, 2025. Bausch Health Companies Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $1.97B.
Buys (12M)
4
$369.63M
Sells (12M)
3
$742.9K
Net Activity
Net Buyer
$368.89M
Active Insiders
4
last 12 mo
BHC Price Chart
BHC Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025↗ | Carson Seana | EVP, General Counsel | Sell | 64,707 | $7.34 | $475.1K | 0 |
| Aug 21, 2025↗ | Lee Frank D. | Director | Sell | 15,912 | $7.66 | $121.9K | 0 |
| Aug 14, 2025↗ | Paulson John | Director | Buy | 34,721,118 | $9.00 | $312.49M | 0 |
| Aug 11, 2025↗ | Paulson John | Director | Buy | 3,243,049 | $6.56 | $21.27M | 0 |
| Jul 15, 2025↗ | Lenar Aimee J. | EVP, US Pharma | Sell | 22,736 | $6.42 | $146.0K | 0 |
| Jun 13, 2025↗ | Paulson John | Director | Buy | 3,564,059 | $5.94 | $21.17M | 0 |
| Jun 10, 2025↗ | Paulson John | Director | Buy | 2,788,608 | $5.27 | $14.70M | 0 |
| Feb 28, 2025↗ | APPIO THOMAS | Chief Executive Officer | Sell | 206,849 | $7.44 | $1.54M | 0 |
| Feb 28, 2025↗ | Barresi John S | SVP, Controller & CAO | Sell | 7,961 | $7.44 | $59.2K | 0 |
| Feb 28, 2025↗ | Carson Seana | EVP, General Counsel | Sell | 49,292 | $7.44 | $366.7K | 0 |
| Nov 29, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 2,132 | $8.37 | $17.8K | 0 |
| Sep 5, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,982 | $6.19 | $24.6K | 0 |
| Sep 5, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 64,707 | $6.19 | $400.8K | 0 |
| Aug 30, 2024↗ | APPIO THOMAS | Chief Executive Officer | Sell | 14,683 | $5.93 | $87.1K | 0 |
| Jun 20, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 1,930 | $6.73 | $13.0K | 0 |
| Feb 29, 2024↗ | APPIO THOMAS | Chief Executive Officer | Sell | 116,982 | $9.89 | $1.16M | 0 |
| Feb 29, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,188 | $9.89 | $31.5K | 0 |
| Feb 29, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 30,556 | $9.87 | $301.6K | 0 |
| Dec 1, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 1,911 | $7.36 | $14.1K | 0 |
| Nov 3, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 377 | $7.57 | $2.9K | 0 |
| Sep 5, 2023↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,982 | $8.35 | $33.2K | 0 |
| Sep 5, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 58,022 | $8.34 | $484.0K | 0 |
| Sep 5, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 43,948 | $8.35 | $367.0K | 0 |
| Sep 1, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 14,111 | $8.46 | $119.4K | 0 |
| Jun 20, 2023↗ | Barresi John S | SVP, Controller & CAO | Sell | 1,929 | $7.40 | $14.3K | 0 |
| Mar 2, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 27,607 | $9.22 | $254.4K | 0 |
| Mar 2, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 11,069 | $9.22 | $102.1K | 0 |
| Mar 2, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 4,001 | $9.25 | $37.0K | 0 |
| Feb 27, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 6,327 | $9.57 | $60.5K | 0 |
| Feb 27, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 2,534 | $9.54 | $24.2K | 0 |
| Jan 3, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 6,310 | $6.28 | $39.6K | 0 |
| Dec 1, 2022↗ | Carson Seana | EVP, General Counsel | Sell | 1,691 | $7.70 | $13.0K | 0 |
| Nov 3, 2022↗ | Carson Seana | EVP, General Counsel | Sell | 334 | $6.45 | $2.2K | 0 |
| Sep 1, 2022↗ | APPIO THOMAS | Chief Executive Officer | Sell | 15,389 | $6.59 | $101.4K | 0 |
| May 10, 2022↗ | PAPA JOSEPH C | Director | Sell | 33,714 | $9.40 | $316.9K | 0 |
| May 3, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 747 | $18.66 | $13.9K | 0 |
| Apr 14, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 1,595 | $22.19 | $35.4K | 0 |
| Mar 15, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 4,846 | $22.20 | $107.6K | 0 |
| Mar 10, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 839 | $22.56 | $18.9K | 0 |
| Mar 8, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 3,889 | $21.76 | $84.6K | 0 |
| Mar 3, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 6,926 | $23.61 | $163.5K | 0 |
| Mar 3, 2022↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 5,564 | $23.61 | $131.4K | 0 |
| Mar 3, 2022↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 1,242 | $23.61 | $29.3K | 0 |
| Mar 3, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 4,074 | $23.61 | $96.2K | 0 |
| Mar 3, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 608 | $23.61 | $14.4K | 0 |
| Mar 3, 2022↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 12,643 | $23.61 | $298.5K | 0 |
| Mar 3, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 4,074 | $23.61 | $96.2K | 0 |
| Mar 2, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 11,077 | $23.37 | $258.9K | 0 |
| Mar 2, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 1,595 | $23.37 | $37.3K | 0 |
| Feb 26, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 16,028 | $24.35 | $390.3K | 0 |
| Feb 26, 2022↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 13,376 | $24.35 | $325.7K | 0 |
| Feb 26, 2022↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 4,834 | $24.35 | $117.7K | 0 |
| Feb 26, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 15,809 | $24.14 | $381.6K | 0 |
| Feb 26, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 1,958 | $24.35 | $47.7K | 0 |
| Feb 26, 2022↗ | PAPA JOSEPH C | Chairman & CEO | Sell | 131,855 | $24.34 | $3.21M | 0 |
| Feb 26, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 8,925 | $24.35 | $217.3K | 0 |
| Feb 15, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 3,251 | $25.02 | $81.3K | 0 |
| Jan 18, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 3,251 | $26.63 | $86.6K | 0 |
| Dec 15, 2021↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 3,461 | $24.49 | $84.8K | 0 |
| Nov 30, 2021↗ | Miller Steven D | Director | Buy | 60,000 | $24.23 | $1.45M | 0 |
| Oct 1, 2021↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 283 | $28.60 | $8.1K | 0 |
| Sep 13, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 8,559 | $28.88 | $247.2K | 0 |
| Aug 27, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 5,017 | $28.95 | $145.2K | 0 |
| Aug 27, 2021↗ | Spurr Robert | President, Salix | Sell | 1,278 | $28.95 | $37.0K | 0 |
| Aug 5, 2021↗ | VON ESCHENBACH ANDREW C. | Director | Buy | 1,400 | $25.94 | $36.3K | 0 |
| Aug 4, 2021↗ | DE SCHUTTER RICHARD U | Director | Buy | 10,000 | $25.01 | $250.1K | 0 |
| Jun 11, 2021↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 17,000 | $31.68 | $538.6K | 0 |
| Jun 2, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 121,198 | $31.83 | $3.86M | 0 |
| May 26, 2021↗ | WECHSLER AMY B | Director | Sell | 11,037 | $31.78 | $350.8K | 0 |
| Mar 11, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 796 | $32.82 | $26.1K | 0 |
| Mar 8, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 21,960 | $32.97 | $724.0K | 0 |
| Mar 8, 2021↗ | APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 17,480 | $32.97 | $576.3K | 0 |
| Mar 8, 2021↗ | Eldessouky Sam | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,361 | $32.97 | $242.7K | 0 |
| Mar 8, 2021↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 12,461 | $32.97 | $410.8K | 0 |
| Mar 8, 2021↗ | Herendeen Paul | EVP and CFO | Sell | 59,519 | $32.97 | $1.96M | 0 |
| Mar 8, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 231,188 | $32.97 | $7.62M | 0 |
| Mar 1, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 5,367 | $31.42 | $168.6K | 0 |
| Mar 1, 2021↗ | APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 5,436 | $31.42 | $170.8K | 0 |
| Mar 1, 2021↗ | Eldessouky Sam | SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,739 | $31.42 | $54.6K | 0 |
| Mar 1, 2021↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 3,313 | $31.42 | $104.1K | 0 |
| Mar 1, 2021↗ | Herendeen Paul | EVP and CFO | Sell | 15,755 | $31.42 | $495.0K | 0 |
| Mar 1, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 28,192 | $31.42 | $885.8K | 0 |
| Mar 1, 2021↗ | Spurr Robert | President, Salix | Sell | 3,252 | $31.42 | $102.2K | 0 |
BHC Insider Buying Activity
The following table shows recent insider purchases of Bausch Health Companies Inc. (BHC) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 14, 2025↗ | Paulson John | Director | Buy | 34,721,118 | $9.00 | $312.49M | 0 |
| Aug 11, 2025↗ | Paulson John | Director | Buy | 3,243,049 | $6.56 | $21.27M | 0 |
| Jun 13, 2025↗ | Paulson John | Director | Buy | 3,564,059 | $5.94 | $21.17M | 0 |
| Jun 10, 2025↗ | Paulson John | Director | Buy | 2,788,608 | $5.27 | $14.70M | 0 |
| Nov 30, 2021↗ | Miller Steven D | Director | Buy | 60,000 | $24.23 | $1.45M | 0 |
| Aug 5, 2021↗ | VON ESCHENBACH ANDREW C. | Director | Buy | 1,400 | $25.94 | $36.3K | 0 |
| Aug 4, 2021↗ | DE SCHUTTER RICHARD U | Director | Buy | 10,000 | $25.01 | $250.1K | 0 |
BHC Insider Selling Activity
The following table shows recent insider sales of Bausch Health Companies Inc. (BHC) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 5, 2025↗ | Carson Seana | EVP, General Counsel | Sell | 64,707 | $7.34 | $475.1K | 0 |
| Aug 21, 2025↗ | Lee Frank D. | Director | Sell | 15,912 | $7.66 | $121.9K | 0 |
| Jul 15, 2025↗ | Lenar Aimee J. | EVP, US Pharma | Sell | 22,736 | $6.42 | $146.0K | 0 |
| Feb 28, 2025↗ | APPIO THOMAS | Chief Executive Officer | Sell | 206,849 | $7.44 | $1.54M | 0 |
| Feb 28, 2025↗ | Barresi John S | SVP, Controller & CAO | Sell | 7,961 | $7.44 | $59.2K | 0 |
| Feb 28, 2025↗ | Carson Seana | EVP, General Counsel | Sell | 49,292 | $7.44 | $366.7K | 0 |
| Nov 29, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 2,132 | $8.37 | $17.8K | 0 |
| Sep 5, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,982 | $6.19 | $24.6K | 0 |
| Sep 5, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 64,707 | $6.19 | $400.8K | 0 |
| Aug 30, 2024↗ | APPIO THOMAS | Chief Executive Officer | Sell | 14,683 | $5.93 | $87.1K | 0 |
| Jun 20, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 1,930 | $6.73 | $13.0K | 0 |
| Feb 29, 2024↗ | APPIO THOMAS | Chief Executive Officer | Sell | 116,982 | $9.89 | $1.16M | 0 |
| Feb 29, 2024↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,188 | $9.89 | $31.5K | 0 |
| Feb 29, 2024↗ | Carson Seana | EVP, General Counsel | Sell | 30,556 | $9.87 | $301.6K | 0 |
| Dec 1, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 1,911 | $7.36 | $14.1K | 0 |
| Nov 3, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 377 | $7.57 | $2.9K | 0 |
| Sep 5, 2023↗ | Barresi John S | SVP, Controller & CAO | Sell | 3,982 | $8.35 | $33.2K | 0 |
| Sep 5, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 58,022 | $8.34 | $484.0K | 0 |
| Sep 5, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 43,948 | $8.35 | $367.0K | 0 |
| Sep 1, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 14,111 | $8.46 | $119.4K | 0 |
| Jun 20, 2023↗ | Barresi John S | SVP, Controller & CAO | Sell | 1,929 | $7.40 | $14.3K | 0 |
| Mar 2, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 27,607 | $9.22 | $254.4K | 0 |
| Mar 2, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 11,069 | $9.22 | $102.1K | 0 |
| Mar 2, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 4,001 | $9.25 | $37.0K | 0 |
| Feb 27, 2023↗ | APPIO THOMAS | Chief Executive Officer | Sell | 6,327 | $9.57 | $60.5K | 0 |
| Feb 27, 2023↗ | Carson Seana | EVP, General Counsel | Sell | 2,534 | $9.54 | $24.2K | 0 |
| Jan 3, 2023↗ | Vadaketh Tom George | EVP, Chief Financial Officer | Sell | 6,310 | $6.28 | $39.6K | 0 |
| Dec 1, 2022↗ | Carson Seana | EVP, General Counsel | Sell | 1,691 | $7.70 | $13.0K | 0 |
| Nov 3, 2022↗ | Carson Seana | EVP, General Counsel | Sell | 334 | $6.45 | $2.2K | 0 |
| Sep 1, 2022↗ | APPIO THOMAS | Chief Executive Officer | Sell | 15,389 | $6.59 | $101.4K | 0 |
| May 10, 2022↗ | PAPA JOSEPH C | Director | Sell | 33,714 | $9.40 | $316.9K | 0 |
| May 3, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 747 | $18.66 | $13.9K | 0 |
| Apr 14, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 1,595 | $22.19 | $35.4K | 0 |
| Mar 15, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 4,846 | $22.20 | $107.6K | 0 |
| Mar 10, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 839 | $22.56 | $18.9K | 0 |
| Mar 8, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 3,889 | $21.76 | $84.6K | 0 |
| Mar 3, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 6,926 | $23.61 | $163.5K | 0 |
| Mar 3, 2022↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 5,564 | $23.61 | $131.4K | 0 |
| Mar 3, 2022↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 1,242 | $23.61 | $29.3K | 0 |
| Mar 3, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 4,074 | $23.61 | $96.2K | 0 |
| Mar 3, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 608 | $23.61 | $14.4K | 0 |
| Mar 3, 2022↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 12,643 | $23.61 | $298.5K | 0 |
| Mar 3, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 4,074 | $23.61 | $96.2K | 0 |
| Mar 2, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 11,077 | $23.37 | $258.9K | 0 |
| Mar 2, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 1,595 | $23.37 | $37.3K | 0 |
| Feb 26, 2022↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 16,028 | $24.35 | $390.3K | 0 |
| Feb 26, 2022↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 13,376 | $24.35 | $325.7K | 0 |
| Feb 26, 2022↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 4,834 | $24.35 | $117.7K | 0 |
| Feb 26, 2022↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 15,809 | $24.14 | $381.6K | 0 |
| Feb 26, 2022↗ | Munsch Frederick | SVP, Controller and CAO | Sell | 1,958 | $24.35 | $47.7K | 0 |
| Feb 26, 2022↗ | PAPA JOSEPH C | Chairman & CEO | Sell | 131,855 | $24.34 | $3.21M | 0 |
| Feb 26, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 8,925 | $24.35 | $217.3K | 0 |
| Feb 15, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 3,251 | $25.02 | $81.3K | 0 |
| Jan 18, 2022↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 3,251 | $26.63 | $86.6K | 0 |
| Dec 15, 2021↗ | APPIO THOMAS | CEO, Pharma Business | Sell | 3,461 | $24.49 | $84.8K | 0 |
| Oct 1, 2021↗ | Spurr Robert | U.S. President-Pharma Business | Sell | 283 | $28.60 | $8.1K | 0 |
| Sep 13, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 8,559 | $28.88 | $247.2K | 0 |
| Aug 27, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 5,017 | $28.95 | $145.2K | 0 |
| Aug 27, 2021↗ | Spurr Robert | President, Salix | Sell | 1,278 | $28.95 | $37.0K | 0 |
| Jun 11, 2021↗ | Eldessouky Sam | EVP & Chief Financial Officer | Sell | 17,000 | $31.68 | $538.6K | 0 |
| Jun 2, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 121,198 | $31.83 | $3.86M | 0 |
| May 26, 2021↗ | WECHSLER AMY B | Director | Sell | 11,037 | $31.78 | $350.8K | 0 |
| Mar 11, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 796 | $32.82 | $26.1K | 0 |
| Mar 8, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 21,960 | $32.97 | $724.0K | 0 |
| Mar 8, 2021↗ | APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 17,480 | $32.97 | $576.3K | 0 |
| Mar 8, 2021↗ | Eldessouky Sam | SVP, CHIEF ACCOUNTING OFFICER | Sell | 7,361 | $32.97 | $242.7K | 0 |
| Mar 8, 2021↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 12,461 | $32.97 | $410.8K | 0 |
| Mar 8, 2021↗ | Herendeen Paul | EVP and CFO | Sell | 59,519 | $32.97 | $1.96M | 0 |
| Mar 8, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 231,188 | $32.97 | $7.62M | 0 |
| Mar 1, 2021↗ | ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | Sell | 5,367 | $31.42 | $168.6K | 0 |
| Mar 1, 2021↗ | APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 5,436 | $31.42 | $170.8K | 0 |
| Mar 1, 2021↗ | Eldessouky Sam | SVP, CHIEF ACCOUNTING OFFICER | Sell | 1,739 | $31.42 | $54.6K | 0 |
| Mar 1, 2021↗ | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | Sell | 3,313 | $31.42 | $104.1K | 0 |
| Mar 1, 2021↗ | Herendeen Paul | EVP and CFO | Sell | 15,755 | $31.42 | $495.0K | 0 |
| Mar 1, 2021↗ | PAPA JOSEPH C | CHAIRMAN & CEO | Sell | 28,192 | $31.42 | $885.8K | 0 |
| Mar 1, 2021↗ | Spurr Robert | President, Salix | Sell | 3,252 | $31.42 | $102.2K | 0 |
BHC Insiders
Similar Stocks to BHC
ZTS
Zoetis Inc.
$115.50+0.03%
$50.88B
TEVA
Teva Pharmaceutical Industries Limited
$28.41-3.04%
$36.69B
VTRS
Viatris Inc.
$13.51-1.99%
$15.56B
NBIX
Neurocrine Biosciences, Inc.
$129.78+1.29%
$13.03B
INDV
Indivior Pharmaceuticals Inc
$31.32+1.49%
$4.05B
SUPN
Supernus Pharmaceuticals, Inc.
$49.80-1.30%
$3.08B
PAHC
Phibro Animal Health Corporation
$49.52+1.06%
$1.95B
ANIP
ANI Pharmaceuticals, Inc.
$70.32-3.00%
$1.68B